Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
12 2019
Historique:
received: 16 12 2018
revised: 25 07 2019
accepted: 28 07 2019
pubmed: 10 8 2019
medline: 29 8 2020
entrez: 10 8 2019
Statut: ppublish

Résumé

Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.

Identifiants

pubmed: 31398540
pii: S1556-0864(19)30655-0
doi: 10.1016/j.jtho.2019.07.025
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2109-2119

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Anne-Marie C Dingemans (AC)

Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands. Electronic address: a.dingemans@erasmusmc.nl.

Lizza E L Hendriks (LEL)

Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands.

Thierry Berghmans (T)

Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Brussels, Belgium; Jules Bordet Institute, Brussels Free University, Brussels, Belgium.

Antonin Levy (A)

Department of Radiation Oncology, Gustave Roussy, Thoracic Oncology Institute (IOT), Villejuif, France; Paris Saclay University, Saint-Aubin, France.

Baktiar Hasan (B)

European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

Corinne Faivre-Finn (C)

The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom.

Matteo Giaj-Levra (M)

Respiratory Oncology Unit, Department of Thoracic and Vascular disease, Grenoble Alpes University Hospital, Grenoble, France.

Niccolò Giaj-Levra (N)

Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy; Department of Oncology, University of Turin, Torino, Italy.

Nicolas Girard (N)

Department of Medical Oncology, Institute Curie, Thorax Institute Curie Montsouris, Paris, France.

Laurent Greillier (L)

Multidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital (APHM), Marseille, France; Aix Marseille University, Marseille, France.

Sylvie Lantuéjoul (S)

Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France; Université Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, Grenoble France.

John Edwards (J)

Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, United Kingdom.

Mary O'Brien (M)

Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom.

Martin Reck (M)

Department of Thoracic Oncology, Airway Research Center North, German Center of Lung Diseases, Lung Clinic, Grosshansdorf, Germany.

Egbert F Smit (EF)

dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Paul Van Schil (P)

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, B-2650 Edegem (Antwerp), Belgium.

Pieter E Postmus (PE)

Department of pulmonology, Leiden University Medical Center, Leiden, The Netherlands.

Sara Ramella (S)

Radiation Oncology, Campus Bio-Medico University, Rome, Italy.

Yolande Lievens (Y)

Radiation Oncology Department, Ghent University Hospital Ghent, Belgium; Ghent University, Ghent, Belgium.

Mina Gaga (M)

Seventh Respiratory Medicine Dept, Athens Chest Hospital Sotiria, Athens, Greece; European Respiratory Society, Lausanne, Switzerland.

Nir Peled (N)

The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Cancer Center, Beer-Sheva, Israel; Ben Gurion University, Beer-Sheva, Israel.

Giorgio V Scagliotti (GV)

Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.

Suresh Senan (S)

Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, The Netherlands.

Luiz Paz-Ares (L)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.

Fiona McDonald (F)

Department of Radiotherapy, Royal Marsden Hospital, London, United Kingdom.

Simon Ekman (S)

Thoracic Oncology Center, Karolinska University Hospital/ Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.

Tanja Cufer (T)

University Clinic Golnik, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Slovenia.

Hester Gietema (H)

GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiology, Maastricht University Medical Center+, Maastricht, The Netherlands.

Maurizio Infante (M)

Thoracic Surgery Dept. University and Hospital Trust - Ospedale Borgo Trento, Verona, Italy.

Rafal Dziadziuszko (R)

Department of Oncology and Radiotherapy, Medical University of Gdansk, 80-211 Gdansk, Poland.

Solange Peters (S)

Oncology Department, University Hospital (CHUV), 1011 Lausanne, Switzerland.

Ramon Rami Porta (RR)

Department of Thoracic Surgery, Mútua Terrassa University Hospital, University of Barcelona, Terrassa, Terrassa, Barcelona, Spain; Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain.

Johan Vansteenkiste (J)

Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.

Christophe Dooms (C)

Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium.

Dirk de Ruysscher (D)

GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands.

Benjamin Besse (B)

Paris Saclay University, Saint-Aubin, France; Department of cancer medicine, Gustave Roussy, Villejuif, France.

Silvia Novello (S)

Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH